Malcolm Mitchell is a graduate of Newcastle Medical School, following a decade in the NHS , he joined the pharmaceutical industry over 30 years ago, with positions in Pfizer, NAPP and Lilly. He has been working in clinical pharmacology at Eli Lilly for the past 20 years. He has been involved in ongoing drug development for many aspects of clinical pharmacology through the portfolio. This includes most of the studies performed from FIH through to BE for formulation change, working with both small molecule NCEs and biologicals.
He continues to be involved in development of biologicals and with Lilly biosimilar insulin as an advisor..